The pipeline for the treatment of wet age-related macular degeneration includes therapies that focus on new molecular targets. Carl J. Danzig, MD, FASRS, discusses a tyrosine kinase inhibitor.

This activity is supported by an independent medical education grant from Ocular Therapeutix.

Click here to view the webinar event, which includes images from the talk.

Want to view more education? Click here.